A Phase 2 interventional study of Placebo and Tetrodotoxin in Pain, Peripheral Neuropathy and Neuropathic Pain, sponsored by Wex Pharmaceuticals Inc.. Terminated at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Wex Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.
Among the 291 studies in Neuralgia with a site in United States, this one is the 58th largest by enrollment of the 261 interventional ones that give a count, is one of 17 that started in 2012, is one of 78 in phase 2, and was the 83rd registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 94 · Phase 3 26 · Phase 4 14
First in 1993; this study’s year is marked. 17 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 52 across 831 interventional studies indexed under Neuralgia.
Median enrollment 40 across the 261 interventional studies, 53 across the 28 observational. Of the 193 that completed or were terminated, 86 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 291 have an industry lead sponsor. The 10 most frequent:
Wex Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Wex Pharmaceuticals Inc. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
27 of the studies in Neuralgia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696443Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | 2027-01-25 |
| NCT07231419Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | 2027-04-06 |
| NCT06628908Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | 2027-05-31 |
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 291 studies in Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing is often either decreased or discontinued potentially affecting tumor responsiveness, prognosis, and survival.
There is an unmet medical need for treatment of cancer patients with chemotherapy induced neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic pain caused by chemotherapy.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
This study's enrollment of 125 is above the median of 52 across 831 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →Wex Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for injection (1 ml volume), twice a day for four consecutive days.
Drug: Placebo
Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Drug: Tetrodotoxin
Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Drug: Tetrodotoxin
Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Drug: Placebo · Drug: Tetrodotoxin
Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
Drug: Tetrodotoxin
Sham treatment acting as control arm
Also known as: placebo for injection
Comparison of different dosages of Tetrodotoxin
Also known as: TTX for injection
Change From Baseline in Patient Reported Outcome for Pain at Day 22 to Day 28.
The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).
Time frame: Day 22 to Day 28
| Milestone | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) |
|---|---|---|---|---|---|
| Started | 25 | 25 | 24 | 25 | 26 |
| Completed | 25 | 23 | 24 | 24 | 25 |
| Not completed | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 |
The primary efficacy endpoint for Part I was the change from baseline in weekly average NPRS scores at 22 to 28 days after treatment. Baseline was defined as the average of NPRS scores for the last 7 days prior to dosing. Pain was assessed using a Numerical Pain Rating Scale (NPRS) with a range of 0 (no pain) to 10 (extreme pain).
| 11 point units on a scale | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) |
|---|---|---|---|---|---|
| Baseline | 6.662 ± 1.4832 | 6.285 ± 1.3312 | 7.012 ± 1.3706 | 6.240 ± 1.1743 | 6.255 ± 1.3561 |
| Mean Scores for Days 22-28 | 5.323 ± 2.2765 | 5.005 ± 2.0451 | 5.987 ± 2.2531 | 4.566 ± 2.4931 | 4.749 ± 1.7701 |
| Change from Baseline in Mean Scores for Days 22-28 | -1.339 ± 2.0681 | -1.269 ± 1.3959 | -1.052 ± 1.5742 | -1.682 ± 2.3231 | -1.529 ± 1.8203 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Twice Daily) | — | 1/25 (4%) | 18/25 (72%) |
| Low Dose Tetrodotoxin (Twice Daily) | — | 0/25 (0%) | 21/25 (84%) |
| Mid-range Dose of Tetrodotoxin (Twice Daily) | — | 1/24 (4.2%) | 22/24 (91.7%) |
| Max Dose Tetrodotoxin (Once Daily) | — | 0/25 (0%) | 20/25 (80%) |
| Max Dose Tetrodotoxin (Twice Daily) | — | 1/26 (3.8%) | 24/26 (92.3%) |
| Event | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) |
|---|---|---|---|---|---|
| Metastatic carcinoma of bladder and Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/25 | 1/24 | 0/25 | 0/26 |
| Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/25 | 0/25 | 0/24 | 0/25 | 0/26 |
| Viral upper respiratory tract infectionInfections and infestations | 0/25 | 0/25 | 0/24 | 0/25 | 1/26 |
| Event | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) |
|---|---|---|---|---|---|
| Paraesthesia OralNervous system disorders | 3/25 | 4/25 | 9/24 | 10/25 | 11/26 |
| ParaesthesiaNervous system disorders | 6/25 | 5/25 | 7/24 | 5/25 | 10/26 |
| Hypoaesthesia OralNervous system disorders | 3/25 | 5/25 | 7/24 | 6/25 | 10/26 |
| headacheNervous system disorders | 5/25 | 6/25 | 3/24 | 1/25 | 9/26 |
| dizzinessNervous system disorders | 5/25 | 3/25 | 4/24 | 3/25 | 8/26 |
| HypoaesthesiaNervous system disorders | 2/25 | 2/25 | 1/24 | 2/25 | 1/26 |
| Age, Continuous(years) | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) | Total |
|---|---|---|---|---|---|---|
| Mean | 59.0 ± 10.3 | 59.1 ± 10.29 | 61.4 ± 10.01 | 60.4 ± 10.28 | 60.6 ± 11.05 | 60.1 ± 10.28 |
| Sex: Female, Male(Participants) | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) | Total |
|---|---|---|---|---|---|---|
| Female | 15 | 16 | 15 | 15 | 16 | 77 |
| Male | 10 | 9 | 9 | 10 | 10 | 48 |
| Region of Enrollment(participants) | Placebo (Twice Daily) | Low Dose Tetrodotoxin (Twice Daily) | Mid-range Dose of Tetrodotoxin (Twice Daily) | Max Dose Tetrodotoxin (Once Daily) | Max Dose Tetrodotoxin (Twice Daily) | Total |
|---|---|---|---|---|---|---|
| United States | 25 | 25 | 24 | 25 | 26 | 125 |
The record gives a start of Jul 2012, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tetrodotoxin
Wex Pharmaceuticals Inc.